As of 2026-05-21, the EV/EBITDA ratio of Cara Therapeutics Inc (CARA) is 0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CARA's latest enterprise value is -13.59 mil USD. CARA's TTM EBITDA according to its financial statements is -61.10 mil USD. Dividing these 2 quantities gives us the above CARA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.1x - 9.8x | 8.2x |
| Forward P/E multiples | 10.5x - 13.8x | 12.4x |
| Fair Price | (132.09) - (123.26) | (129.41) |
| Upside | -2582.8% - -2417.0% | -2532.6% |
| Date | EV/EBITDA |